Skip to main content
. 2021 Aug 28;11(18):9162–9176. doi: 10.7150/thno.59605

Figure 6.

Figure 6

PRMT5 inhibitor EPZ015666 suppressed cervical cancer growth. (A-B) U14 cells were cultured in the indicated concentrations of EPZ015666 for 72 h. (A) Effect of EPZ015666 on the viability and proliferation of U14 cells was analyzed by CellTiter-Glo luminescent assay and CCK-8 Cell Counting assay, respectively. (B) Expression of PD-L1 on U14 cells was analyzed by flow cytometry after IFN-γ stimulation. (C-E) On day 3 after inoculation of U14 cells, EPZ015666 was intraperitoneally injected into 6-week-old female C57BL/6 mice every day (n = 5 for each group). (C) A line graph shows the tumor growth curve of mice. Images (D) and weight (E) of the resected tumor at day 12 after inoculation. Data are representative of two independent experiments. Values are presented as the mean ± SEM. (F) Schematic diagram of the mechanism of PRMT5 in promoting the development of cervical cancer. *P < 0.05, **P < 0.01, and *** P < 0.001.